Top five promising multiple myeloma research studies presented at ASCO 2018
Dr. S. Vincent Rajkumar (Mayo Clinic, Rochester, MN) discusses which five trials he found to be most significant at ASCO 2018:
- Using bb2121 for relapse refractory multiple myeloma patients, which showed an increased median survival rate of one year.
- Changing the dosage of carfilzomib from twice a week to once a week, making it easier for patients to take...
- And from same study as above, using high-dose versus low-dose carfilzomib. Results indicated that a higher dose is not necessarily better, and that it still needs to be studied further in combinations.
- Using a subcutaneous method of treatment is more effective than an intravenous method of daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma.
- Using the triplet combination of pomalidomide + bortezomib + dexamethasone as opposed to bortezomib + dex delivered better patient outcomes.
ABOUT S. VINCENT RAJKUMAR, MD
S. Vincent Rajkumar, M.D., is a Faculty hematologist/oncologist at the Mayo Clinic in Rochester, MN. He conducts research in multiple myeloma and related disorders. He has served as the principal investigator for pivotal clinical trials for the treatment of myeloma. Visit Dr. Rajkumar’s full biography.